Products

Trade name

Azzalure, 10 Speywood units/0.05 ml, powder for solution for injection

Company

Q-Med, a Galderma Division

Description

Botulinum toxin type A^a 10 Speywood units ^b/0.05 ml of reconstituted solution

Vial of 125 units

The Speywood units of Azzalure are specific to the preparation and are not interchangeable with other preparations of botulinum toxin

Pharmaceutical Form:

Powder for solution for injection

The powder is white

Posology:

The recommended dose is 50 Speywood units (0.25 ml of reconstituted solution) of Azzalure to be divided into 5 injection sites, 10 Speywood units (0.05 ml of reconstituted solution) are to be administered intramuscularly into each of the 5 sites: 2 injections into each corrugator muscle and one into the procerus muscle

During the clinical development of Azzalure, more than 2,600 patients were included in the different clinical trials

In clinical studies, 1,907 patients with moderate to severe glabellar lines have been treated at the recommended dose of 50 Speywood units. Of these, 305 were treated with 50U in two pivotal phase III double-blind placebo-controlled studies and 1,200 treated with 50U in a long-term open-label repeated-dose phase III study. The remaining patients were treated in supportive and dose-ranging studies [1–6]

Intended use

Azzalure is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at frown, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient

Onset of response and duration

The median time to onset of response was 2–3 days following treatment, with the maximum effect observed at day 30. In two pivotal placebo-controlled phase III studies, Azzalure injections significantly reduced the severity of glabellar lines for up to 4 months. The effect was still significant after 5 months in one of the two pivotal studies. Treatment interval should not be more frequent than every three months

^a Clostridium botulinum toxin A haemagglutinin complex

^bOne Speywood unit (U) is defined as the median lethal peritoneal dose in mice (LD50)

Azzalure: Reference

Ascher B, Zakine B, Kestemont P et al. (2004) A multicentre, randomized, double-blind, placebo-controlled study of efficacy and safety of three doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad of Dermatol 51(2):223–33

Ascher B, Zakine B, Kestemont P et al. (2005) Botulinum tox A in the treatment of glabellar lines: scheduling the next injection. Aesth Surg J 25:365–375

Monheit G, Carruthers A, Brandt F, Rand R (2007) A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33(1):S51–S59

Moy R, Maas C, Monheit G, Huber B (2009) Long-term safety and efficacy of a new botulinum toxin type A in treatment glabellar lines. Arch Facial Plast Surg 11(2):77–83

Rzany B, Dill-Mueller D, Grablowitz D et al. (2007) Repeated botulinum toxin A injections for the treatment lines in the upper face: a retrospective study of 103 treatments in 945 patients. Dermatol Surg 33:S18–S25

Rzany B, Asher B, Monheit GD (2010) Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a Clinical overview. JEADV 24(1):1–14

24.2 Belotero Range

24.2.1 Belotero Basic Filler

Trade name	Belotero basic
Volume/package	Cross-linked sodium hyaluronate: 22.5 mg/ml in 1-ml glass syringe
Company	Merz Pharma
Certifications	CE, FDA
Commercialization	2006
	Austria, Germany, Italy, Russia, Switzerland, UK and USA
Description	Belotero Basic is a sterile, pyrogenic, viscoelastic clear colourless transparent, isotonic gel. Belotero Basic consists of cross-linked sodium hyaluronate of non-animal origin Belotero has a CPM^® technology based on a dynamic, double cross-linking process of the cohesive monophasic hyaluronic acid gel with the stabilizer BDDE1
Description	The unique Cohesive Polydensified Matrix (CPM^®) provides a stable, cohesive gel and provides outstanding product qualities as low-viscosity properties that make it able to fill in even the tightest intradermal spaces, homogenous distribution into the dermis, smooth transitions between treated and untreated areas and low injection pressure making treatment nearly pain-free
Intended use	Belotero Basic is an injectable implant indicated for use to increase the volume of skin tissue which enables: the correction of facial depressions, either due to injury or age-related (scarring, moderate or deep wrinkles, furrows), remodelling of the contours of the face by injection into facial areas such as the cheeks, chin, etc., increase in lip volume (the border of the red part of the lip, increasing roundness)
Duration	No published data
Needle TWN	2 27 G½ (0.4 × 1.3 mm) (supplied)
Suggested cannulas	30 G 1 inch; 27 G 1½ inch; 25 G 1½ inch; 25 G 2 inch (not supplied)

24.2.2 Belotero Soft Filler

Trade name	Belotero soft
Company	Merz Pharma
Volume/Package	Cross-linked sodium hyaluronate: 20 mg/ml in 1-ml glass syringe
Certifications	CE, FDA
First commercialization	2006
	Austria, Germany, Italy, Russia, Switzerland and UK
Description	Belotero soft is a sterile, pyrogenic, viscoelastic clear colourless transparent, isotonic gel. Belotero Basic consists of cross-linked sodium hyaluronate of non-animal origin Belotero has a CPM^® technology based on a dynamic, double cross-linking process of the cohesive monophasic hyaluronic acid gel with the stabilizer BDDE1
Description	The unique Cohesive Polydensified Matrix (CPM^®) provides a stable, cohesive gel and provides outstanding product qualities as low-viscosity properties that make it able to fill in even the tightest intradermal spaces, homogenous distribution into the dermis, smooth transitions between treated and untreated areas and low injection pressure making treatment nearly pain-free
Intended use	Belotero Soft is an injectable implant indicated for use to increase the volume of skin tissue which enables: to correct shallow facial depressions, either due to injury or age-related (scars, fine lines, crow’s feet wrinkles), to retouch a correction undertaken with Belotero Basic, immediately or a few weeks after the first injection
Duration	No published data
Needle TWN	2 30 G1″/2 (0.3 × 13 mm) (supplied)
Suggested cannulas	30 G 1 inch; 27 G 1½ inch (not supplied)

24.2.3 Belotero Intense Filler

Trade name	Belotero intense
Company	Merz Pharma
Volume/Package	Cross-linked sodium hyaluronate: 25.5 mg/ml in 1-ml glass syringe
Certifications	CE, FDA
First commercialization	2009
	Austria, Germany, Italy, Russia, Switzerland, UK and USA
Description	Belotero soft is a sterile, pyrogenic, viscoelastic clear colourless transparent, isotonic gel. Belotero Basic consists of cross-linked sodium hyaluronate of non-animal origin Belotero has a CPM^® technology based on a dynamic, double cross-linking process of the cohesive monophasic hyaluronic acid gel with the stabilizer BDDE1
Description	The unique Cohesive Polydensified Matrix (CPM^®) provides a stable, cohesive gel and provides outstanding product qualities as low-viscosity properties that make it able to fill in even the tightest intradermal spaces, homogenous distribution into the dermis, smooth transitions between treated and untreated areas and low injection pressure making treatment nearly pain-free
Intended use	Belotero Intense is an injectable implant indicated to restore or significantly improve deep folds and augment face skin volume defects which enables: the correction of facial depressions, either due to injury or age-related (scarring, deep wrinkles, furrows), remodelling of the contours of the face by injection into facial areas such as the cheeks, chin, etc., lip enhancement especially the border of the red part of the lip
Duration	No published data
Needle TWN	2 21 Gy 2 (0.4 × 13 mm) needles (supplied)
Suggested cannulas	27 G 1½ inch; 25 G 2 inch (not supplied)

Belotero: Reference

Huber J. Efficacy of combined treatment using hyaluronic acid (belotero^® soft) and botulinium toxin type A (xeomin^®) to optimize aesthetic outcome in radial upperlid lines. Kosmetische Medizin 3(10):4–10

Pavicic T, Ruzicka T, Korting H–K, Gauglitz G. Monophasic (2010) Cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients. J Drugs Dermatol 9(6): 690–695

Prager W, Steinkraus V (2010) A prospective, rater-blind, randomized comparison of the effectiveness and tolerability of belotero^® basic versus restylane^® for correction of nasolabial folds. Eur J Dermatol

Reinmüller J, Wolters M, Lampe H, Steinkraus V, Dirting K, Sommer B, Leva S, Flatau-Baque B (2007)Poster presented at the 21st World Congress of Dermatology, Buenos Aires, Argentina, Sept 30–Oct 5 2007. (This was then published as a supplement to Dermatology News: Kammerer S (2007) Belotero^®: a CPM^®-technology based HA-filler. easy handling, smooth spreading in the tissues. Dermatol News 2007(11):2–3)

Taufig AZ, Szöke A, Kühnel W (2009) A new strategy to detect intradermal reactions after injection of resorbable dermal fillers. J Ästhetische Chirurgie 2:29–36

24.3 Bocouture

24.3.1 Botulinum Toxin Merz-A Drug

Trade name	Bocouture, Xeomin, Xeomin cosmetic and Xeomeen
Company	Merz Pharma
Volume/Package	1 vial containing 50 LD₅₀ units of Botulinum toxin type A 0.1 ml solution contains 4 LD₅₀ units of Botulinum toxin type A (150 kD) reconstituted in 1.25 ml
Certifications	FDA
First commercialization	2011
	Argentina (Xeomin), Austria (Bocouture), Belgium (Bocouture), France (Bocouture), Germany (Bocouture), Italy (Bocouture), Mexico (Xeomeen), Netherlands (Bocouture), Portugal (Bocouture), Russia (Xeomin), Spain (Bocouture), Sweden (Bocouture), UK (Bocouture) and USA (Xeomin)
Description	Bocouture^® Botulinum Toxin Type A is a highly pure neuromodulator formulation that contains only active neurotoxin and that is free from complexing proteins; thanks to a precision engineering process, Bocouture contains pure (150 kD) neurotoxin. Due to its purity, Bocouture^® could be beneficial in reducing the risk of non-response or a decrease in response, especially in long-term treatment
Description	Bocouture^® is highly stable and the only botulinum toxin type A that does not have to be refrigerated during transportation or storage Complete recovery of endplate function/impulse transmission after injection normally occurs within 3–4 months as nerve terminals sprout and reconnect with the endplate
Intended use	Bocouture is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at frown (glabellar frown lines) in adults below 65 years when the severity of these lines has an important psychological impact for the patient
Duration	An improvement in the glabellar frown lines generally takes place within 2–3 days with the maximum effect observed on day 30. The effect lasts up to 4 months after the injection. The intervals between treatments should not be shorter than 3 months
Needle TWN	Reconstituted Bocouture is injected using a thin sterile needle (e.g. 30-gauge needle) (not supplied)
Suggested cannulas

Bocouture Botulinum Toxin-A Drug: Reference

Bocouture SmPC June 2010

Frevert J (2010) Drugs in R&D 10(2):1–7

Grein S et al. Mov Discord 23; Supplement 1, S24 (2008) Xeomin is stable without refrigeration. Complexing proteins are not required for stability of Botulinum neurotoxin type A preparations

24.4 Emervel Range

Trade name	Emervel touch
Company	Q-Med, a Galderma Division
Volume/Package	1 ml
Certifications	CE-2010
First commercialization	2011
Description	Emervel^® Touch is a viscoelastic, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction
Intended use	Emerve^® Touch is an injectable dermal filler used to augment the volume of facial tissues. Emervel^® Touch is indicated for injection into the superficial dermis for the correction of superficial wrinkles
Duration	Emervel^® Touch increases the volume of the dermis for a period of 6–9 months
Needle UTW	30 G½ (supplied)

Trade name	Emervel classic
Company	Q-Med, a Galderma Division
Volume/Package	1 ml
Certifications	CE-2010
First commercialization
Description	Emervel^® Classic is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction
Intended use	Emervel^® Classic is an injectable dermal filler used to augment the volume of facial tissues. It is indicated for injection into the mid-dermis for the treatment of moderate to deep wrinkles, or to redefine the shape of the face (cheekbones, tear trough, or lips)
Duration	Emervel^® Classic increases the volume of the dermis for a period of 6–9 months
Needle	30 G½ (supplied)

Trade name	Emervel classic lidocaine
Company	Q-Med, a Galderma Division
Volume/Package	1 ml
Certifications	CE-2010
First commercialization
Description	Emervel^® Classic lidocaine is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system. 0.3 % lidocaine is added to the formulation to diminish the pain resulting from the injection during the treatment Emervel^® Classic lidocaine is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction
Intended use	Emervel^® Classic lidocaine is an injectable dermal filler used to augment the volume of facial tissues. It is indicated for injection into the mid-dermis for the treatment of moderate to deep wrinkles, or to redefine the shape of the face (cheekbones, tear trough, or lips)
Duration	Emervel^® Classic lidocaine increases the volume of the dermis for a period of 6–9 months
Needle UTW	30 G½ (supplied)

Trade name	Emervel deep
Company	Q-Med, a Galderma Division
Volume/Package	1 ml
Certifications	CE-2010
First commercialization	2011
Description	Emervel^® Deep is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system
Description	Emerve^® Deep is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction
Intended use	Emerve^® Deep is an injectable dermal filler used to augment the volume of facial tissues. Emerve^®Deep is indicated for injection into the deep dermis for the correction of moderate to deep wrinkles, or to redefine the shape of the face (cheekbones, tear trough, or lips)
Duration	Emerve^® Deep increases the volume of the dermis in a durable manner, for a period of 6–9 months
Needle UTW	27 G½ (supplied)
Cost

Trade name	Emervel deep lidocaine
Company	Q-Med, a Galderma Division
Volume/Package	1 ml
Certifications	CE-2010
First commercialization	2011
Description	Emerve^® Deep lidocaine is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system. 0.3 % lidocaine is added to the formulation to diminish the pain resulting from the injection during the treatment Emerve^® Deep lidocaine is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction
Intended use	Emerve^® Deep lidocaine is an injectable dermal filler used to augment the volume of facial tissues. Emervel^® Deep lidocaine is indicated for injection into the deep dermis for the correction of moderate to deep wrinkles, or to redefine the shape of the face (cheekbones, tear trough, or lips)
Duration	Emerve^® Deep lidocaine increases the volume of the dermis in a durable manner, for a period of 6–9 months
Needle UTW	27 G½ (supplied)

Trade name	Emervel volume
Company	Q-Med, a Galderma Division
Volume/Package	2 ml
Certifications	CE-2010
First commercialization	2011
Description	Emerve^® Volume is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system Emerve^® Volume increases the volume of the tissues. Emervel^® Volume is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction
Intended use	Emerve^® Volume is an injectable dermal filler used to augment the volume of facial tissues. Emervel^® Volume is indicated for injection into the supraperiostic zone or subcutaneous fat tissue for the correction of facial volume (cheeks and chin)
Duration	Not provided in IFU
Needle UTW	23 1 UTW (supplied)
Cost

Trade name	Emervel volume lidocaine
Company	Q-Med, a Galderma Division
Volume/Package	2 ml
Certifications	CE-2010
First commercialization	2011
Description	Emerve^® Volume is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system. 0.3 % lidocaine is added to the formulation to diminish the pain resulting from the injection during the treatment Emerve^® Volume increases the volume of the tissues. Emervel^® Volume is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction
Intended use	Emerve^® Volume is an injectable dermal filler used to augment the volume of facial tissues. Emervel^® Volume is indicated for injection into the supraperiostic zone or subcutaneous fat tissue for the correction of facial volume (cheeks, chin)
Duration	Not provided in IFU
Needle UTW	23 1 UTW (supplied)

Trade name	Emervel lips
Company	Q-Med, a Galderma Division
Volume/Package	1 ml
Certifications	CE-2010
First commercialization	2011
Description	Emerve^® Lips is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system Emerve^® Lips is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction
Intended use	Emerve^® Lips is an injectable dermal filler used to restore and/or augment the volume of the lips
Duration	Emerve^® Lips increases the volume of the dermis for a period of 6–9 months
Needle	27 G½ (supplied)

Trade name	Emervel lips lidocaine
Company	Q-Med, a Galderma Division
Volume/Package	1 ml
Certifications	CE-2010
First commercialization	2011
Description	Emerve^® Lips lidocaine is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system. 0.3 % lidocaine is added to the formulation to diminish the pain resulting from the injection during the treatment Emerve^® Lips lidocaine is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction
Intended use	Emerve^® Lips lidocaine is an injectable dermal filler used to restore and/or augment the volume of the lips
Duration	Emerve^® Lips lidocaine increases the volume of the dermis for a period of 6–9 months
Needle UTW	27 G½ (supplied)

Emervel: Reference

Ascher B, Bayerl C, Brun P, Kestemont P, Rzany B, Poncet M, Guennoun M, Podda M (2011) Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of severe nasolabial lines—6 month interim results of a randomized, evaluator-blinded, intra-individual comparison study. J Cosmet Dermatol 10(2):94–98

Rzany B (2012) Emervel^®: full-face rejuvenation with a range of customized hyaluronic acid fillers. J Drugs Dermatol 11(1 Suppl):S4

Rzany B, Bayerl C, Bodokh I, Boineau D, Dirschka T, Queille-Roussel C, Sebastian M, Sommer B, Poncet M, Guennoun M, Podda M (2011) Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of moderate nasolabial folds: 6 month interim results of a randomized, evaluator-blinded, intra-individual comparison study. J Cosmet Laser Ther 13(3):107–112

24.5 Glytone Range

24.5.1 Glytone 1 Filler

Trade name	Glytone 1
Company	Merz Pharma
Volume/Package	HA concentration: 14 mg/ml in 2 2 × 1 ml syringes
Certifications	CE, FDA technology
First commercialization	2009 (P. Fabre) 2012 (Europe, Merz Pharma)
Aree di vendita	France, Italy, Netherlands, Belgium, Luxembourg, Spain and Portugal
Description	Glytone Professional 1 is a sterile non-pyrogenic physiological gel made of non-reticulated high molecular weight hyaluronic acid of non-animal origin. This gel comes in a pre-filled graduated single-use syringe In combination with HA, there are mannitol known as free radical scavenger for a longer duration and stability and glycerol known for its ability to hydrate in a patented-specific product composition
Intended use	Glytone Professional 1 is an injectable implant for the mesotherapy to rehydrate deep layers of the skin through repeated injections into dermo-epidermal junction and superficial dermis Glytone Professional 1 can be injected on face, neck, cleavage and hands
Duration	No published data
Needle TWN	4 × 30 G½ (supplied)
Suggested cannulas	30 G; 27 G (not supplied)
Cost

24.5.2 Glytone 2 Filler

Trade name	Glytone 2
Company	Merz Pharma
Volume/Package	HA concentration: 20 mg/ml in 2 1-ml syringe
Certifications	CE, FDA technology
First commercialization in Italy	2009 (P. Fabre)
First commercialization in Italy	2012 (Merz Pharma)
Aree di vendita	France, Italy, Netherlands, Belgium, Luxembourg, Spain and Portugal
Description	Glytone Professional 2 is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (cross-linking agent: BDDE) of non-animal origin. This gel Glytone 2 is a monophasic filler, and in combination with the cross-linked HA, it contains mannitol known as free radical scavenger for a longer duration and stability and non-cross-linked HA known for its inhibition of matrix-metallo-proteinase which degrades collagen in a patented-specific product composition
Intended use	Glytone Professional 2 filling superficial wrinkles by injection into the superficial and/or mid-dermis injected on face, neck, cleavage and hands
Duration	No published data
Needle TWN	1 × 27 G½; 1 × 30 G ½ (supplied)
Suggested cannulas	30 G; 27 G (not supplied)
Cost

24.5.3 Glytone 3 Filler

Trade name	Glytone 3
Company	Merz Pharma
Volume/Package	HA concentration: 23 mg/ml in 2 1-ml syringe
Certifications	CE, FDA technology
First commercialization	2009 (P. Fabre) 2012 (Merz Pharma, Europe)
Aree di vendita	France, Italy, Netherlands, Belgium, Luxembourg, Spain and Portugal
Description	Glytone Professional 3 is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (cross-linking agent: BDDE) of non-animal origin. This gel Glytone 3 is a monophasic filler, and in combination with the cross-linked HA, it contains mannitol known as free radical scavenger for a longer duration and stability and non-cross-linked HA known for its inhibition of matrix-metalloproteinase which degrades collagen in a patented-specific product composition
Intended use	Glytone Professional 3 is an injectable implant for filling deep wrinkles by injection into the mid- and/or deep dermis and to increase lip volume
Duration	No published data
Needle TWN	2 × 27 G ½; (supplied)
Suggested cannulas	27 G (not supplied)
Cost

24.5.4 Glytone 4 Filler

Trade name	Glytone 4
Company	Merz Pharma
Volume/Package	HA concentration: 24 mg/ml in 2 2x 1 ml syringe
Certifications	CE, FDA technology
First commercialization in Italy	2009 (P. Fabre) 2012 (Merz Pharma)
Aree di vendita	France, Italy, Netherlands, Belgium, Luxembourg, Spain and Portugal
Description	Glytone Professional 4 is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (cross-linking agent: BDDE) of non-animal origin. This gel Glytone 4 is a monophasic filler, and in combination with the cross-linked HA, it contains mannitol known as free radical scavenger for a longer duration and stability and non-cross-linked HA known for its inhibition of matrix-metalloproteinase which degrades collagen in a patented-specific product composition
Intended use	Glytone Professional 4 is an injectable implant for filling deep skin folds, cutaneous depressions, facial localized volume loss by mid-dermal and/or deep dermis injection and for increasing the lips volume
Duration	No published data
Needle TWN	2 × 23 G ¼; 2 × 25 G ^5/8 (supplied)
Suggested cannulas	25 G (not supplied)
Cost

Glytone Range: Reference

Virginie T et al. (2010) Assessment of the clinical efficacy of a hyaluronic acid-based deep wrinkle filler using new instrumental methods. J Cosmetic Therapy 12:195–202

24.6 Hyacorp Range

24.6.1 Hyacorp Filler

Trade name	Hyacorp H 1000
Company	Bioscience GmbH
Volume/Package	10, 2 ml
Certifications	CE
First commercialization	2009
Aree di vendita	All European countries, Japan and Middle East
Description	Hyacorp is a clear and viscous gel supplied in a special syringe of 10 ml/2 ml. The product is for single use only. The gel consists in a form of a cross-linked hyaluronic acid non-animal source. The particle size is approx. 1,000 μ
Intended use	Restoration and contouring of body surfaces The depth of the injection may vary from subcutaneous to supraperiostal administration depending on the treatment site
	• Buttocks
	• Calves
	• Correction of concave deformities
	• Regio zygomatica
Duration	The degree and duration of the correction depend on the character of the defect treated, the tissue stress at the implant site, the depth of the implant into the tissue and the injection technique
Needle TWN	Not supplied
Suggested cannulas	Not supplied

Trade name	HYACORP H/S 500
Company	Bioscience GmbH
Volume/Package	10, 2 ml
Certifications	CE
First commercialization in Italy	2010
Aree di vendita	All European countries, Japan and Middle East
Description	Hyacorp is a clear and viscous gel supplied in a special syringe of 10 ml/2 ml. The product is for single use only. The gel consists in a form of a cross-linked hyaluronic acid non-animal source. The particle size is approx. 500 μ
Intended use	Restoration and contouring of body surfaces The depth of the injection may vary from subcutaneous to supraperiostal administration depending on the treatment site
	• Buttocks
	• Calves
	• Correction of concave deformities
	• Regio zygomatica
Duration	The degree and duration of the correction depend on the character of the defect treated, the tissue stress at the implant site, the depth of the implant into the tissue and the injection technique
Needle TWN	Not supplied
Suggested cannulas	Not supplied

Trade name	Hyacorp L
Company	Bioscience GmbH
Volume/Package	2 ml
Certifications	CE
First commercialization in Italy	2009
Aree di vendita	Italy, all European countries, Japan and Middle East
Description	Hyacorp is a clear and viscous gel supplied in a special syringe of 2 ml. The product is for single use only. The gel consists of cross-linked hyaluronic acid non-animal source. The particle size is approx. 350 μ
Intended use	Restoration of the volume and contour of the body surfaces and the face. The depth of the injection may vary from subcutaneous to supraperiostal administration depending on the treatment site
Duration	The duration of the filling effect can vary and is depending of the depth and area of injection
Needle TWN	22 G × 1 1/4
Suggested cannulas	Not supplied

Trade name	Hyacorp face
Company	Bioscience GmbH
Volume/Package	1 ml
Certifications	CE
First commercialization in Italy	2009
Aree di vendita	All European countries, Japan and Middle East
Description	Hyacorp Face is a clear and viscous gel supplied in a syringe of 1 ml. The product is for single use only. The gel consists of cross-linked hyaluronic acid non-animal source. Particle size approx. 150 μ
Intended use	Hyacorp Face is designed to be used for the restoration of the facial volume and contour. The gel is injected intradermal and lifts the tissue in a natural way. Warning: Hyacorp Face is only intended for intradermal administration. Do not inject intravascularly
Duration	The duration of the filling effect can vary and is depending of the depth and area of injection
Needle TWN	27 G × 12 mm
Suggested cannulas	Not supplied

Trade name	Hyacorp lips
Company	Bioscience GmbH
Volume/Package	1 ml
Certifications	CE
First commercialization in Italy	2009
Aree di vendita	All European countries, Japan and Middle East
Description	Hyacorp Lips is a clear and viscous gel supplied in a syringe of 1 ml. The product is for single use only. The gel consists of cross-linked hyaluronic acid non-animal source. Particle size approx. 150 μ
Intended use	Hyacorp Lips is designed to be used for the restoration of volume and contouring of the Lips. The gel is injected intradermal and lifts the tissue in a natural way. Warning: Hyacorp Lips is only intended for intradermal administration. Do not inject intravascularly
Duration	The duration of the filling effect can vary and is depending of the depth and area of injection
Suggested Needle	30 G Nano needle
Suggested cannulas	Not supplied

Trade name	Hyacorp fine
Company	Bioscience GmbH
Volume/Package	1 ml
Certifications	CE
First commercialization in Italy	2012
Aree di vendita	All European countries, Japan and Middle East
Description	Hyacorp Fine is a sterile, apyrogenic, visco-elastic, biologically compatible (non-immunizing, non-inflammatory, non-toxic) gel implant that is insoluble in water and produced from a hyaluronic acid gained through fermentation
Intended use	Hyacorp Fine is implanted into the medium dermal tissue to supplement the intercellular matrix and the intradermal tissue and to restore lost anatomical structures of the skin. Its mechanism of action is based on the latest biotechnology in the production of highly purified hyaluronic acid
Duration	The duration of the filling effect can vary and is depending of the depth and area of injection
Suggested Needle	34 G Nano needle
Suggested cannulas	Not supplied

Trade name	Ephyal
Company	Bioscience GmbH
Volume/Package	50 ml
Certifications	CE
First commercialization in Italy	2012
Aree di vendita	Italy, Russia and Ukraine
Description	Ephyal Solution is a sterile medical device, certified by the notified body DQS in Frankfurt/Germany with the CE mark 0297. It contains hyaluronic acid non-animal source with a special designed molecular weight
Intended use	Ephyal is indicated for areas with thin and dry skin. Regions to treat are neck, face, décolleté and hands
Duration	No published data. Supposed to be up to 6 months
Suggested Needle	Not supplied